
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Volunteering overseas, Advocate extraordinaire, Another salvo in the co-sleeping wars, The high cost of hazing; Eye on Washington






